MBMonika Biniecka

Monika Biniecka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monika Biniecka has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serotype-dependent bioenergetic and electrophysiological remodelling in iPSC-derived cardiomyocytes from rheumatoid arthritis patients

    by Jan Wolnik, Patrycja Adamska, Aleksandra Oleksy, Anna Magdalena Sanetra, Katarzyna Palus-Chramiec, Marian Henryk Lewandowski, Józef Dulak, Monika Biniecka

    Background: Patients with rheumatoid arthritis (RA) exhibit increased cardiovascular morbidity and mortality that are not fully explained by traditional risk factors, with cardiovascular outcomes differing between seropositive (spRA) and seronegative (snRA) disease. The cellular mechanisms linking chronic inflammation to cardiac dysfunction remain poorly defined, and no patient-specific cardiomyocyte model has resolved cellular phenotypes by RA serotype. Methods: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were generated from healthy donors and patients with spRA and snRA. Bioenergetic and electrophysiological responses to key RA proinflammatory cytokines (TNF-α, IL-1β, IL-6) and anti-rheumatic drugs (adalimumab, tofacitinib) were assessed using Seahorse assays, patch-clamp electrophysiology, multi-electrode array recordings and RT-qPCR. Results: snRA cardiomyocytes exhibited impaired TNF-α-induced oxidative phosphorylation, accompanied by attenuated expression of ATP5B , LDHA and DLD . In contrast, spRA cardiomyocytes showed baseline electrophysiological alterations, including shortened APD90 and increased action-potential triangulation. TNF-α depolarised the maximum diastolic potential in both RA serotypes. At the multicellular level, cytokine effects were serotype-specific: IL-1β selectively prolonged QT interval in spRA monolayers (p < 0.001), whereas IL-6 prolonged QT in snRA (p < 0.05). Both RA serotypes showed impaired TNF-α-driven induction of KCNJ3 and KCNA5 . Adalimumab selectively induced ATP5B in spRA but failed to engage either pathway in snRA, while tofacitinib selectively induced KCNJ3 in healthy but not RA cardiomyocytes. Conclusions: These findings define distinct, serotype-specific pathways of cardiac remodelling in RA that converge on a shared proarrhythmic phenotype, provide a cellular framework for cardiovascular risk in RA and identify candidate mechanisms relevant to therapy-associated cardiovascular safety. Graphical

  • High‐Resolution Imaging and Assessment of Vascular Network in Tri‐Lineage hiPSC‐Derived Cardiac Microtissues

    by Patrycja Adamska, Jan Wolnik, Patryk Chudy, Aleksandra Oleksy, Julia Wierzbicka, Józef Dulak, Monika Biniecka

    Cardiac microtissues (cMTs) are three‐dimensional, self‐organizing structures that recapitulate key features of native heart tissue. cMTs can be generated using induced pluripotent stem cells (iPSCs) technology by combining iPSC‐derived cardiomyocytes (CMs), endothelial cells (ECs), and cardiac fibroblasts (CFs) in a predefined ratio that closely resembles the cellular composition of the heart. Although cMTs lack true vascular perfusion, the incorporation of endothelial cells promotes the spontaneous formation of microvascular‐like networks, which are identifiable within the 3D structure. The presence of vascular endothelial cells within cMTs enhances cardiomyocyte maturation and contraction force, while also making these models valuable in disease modeling, particularly for conditions involving endothelial dysfunction. High‐resolution imaging of cMTs allows detailed visualization of cellular components and analysis of vascular‐like structures, providing critical insights into the complex interactions between cardiac cells and their microenvironment. Here, we present protocols for the generation and examination of scaffold‐free, vascularized cMTs derived from human iPSCs. First, we outline the steps for aggregation of pre‐differentiated iPSC‐CMs, iPSC‐ECs, and iPSC‐CFs to form vascularized cMTs. We then detail the downstream methodology for fluorescence labeling of both whole‐mount and sectioned cMTs, followed by image acquisition, visualization, and capture using confocal microscopy. Finally, we demonstrate image analysis, and the measurement of the capillary‐like networks using ImageJ (FIJI) software, with 3D modeling and Z ‐stack processing modules. © 2025 Wiley Periodicals LLC. Basic Protocol 1 : Formation of tri‐lineage hiPSC‐derived cardiac microtissues Basic Protocol 2 : Immunofluorescence staining of whole‐mount and sectioned cardiac microtissues Alternate Protocol : Counterstaining of whole‐mount cardiac microtissues for cryo‐sectioning Basic Protocol 3 : Cardiac microtissue imaging setup and data acquisition using confocal microscopy Basic Protocol 4 : Assessment of the vascular network in cardiac microtissues

  • Open Access

    A novel 3D cardiac microtissue model for investigation of cardiovascular complications in rheumatoid arthritis

    by Jan Wolnik, Patrycja Adamska, Aleksandra Oleksy, Anna Magdalena Sanetra, Katarzyna Palus-Chramiec, Marian Henryk Lewandowski, Józef Dulak, Monika Biniecka

    Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects not only the joints but also has significant cardiovascular (CV) manifestations. The mechanistic interplay between RA and cardiovascular complications is not yet well understood due to the lack of relevant in vitro models. In this study, we established RA cardiac microtisses (cMTs) from iPSC-derived cardiomyocytes (CMs), endothelial cells (ECs) and cardiac fibroblasts (CFs) to investigate whether this fully human 3D multicellular system could serve as a platform to elucidate the connection between RA and CV disorders. PBMC and FLS from healthy and RA donors were reprogrammed to hiPSCs with Sendai vectors. hiPSCs pluripotency was assessed by IF, FACS, spontaneous embryoid bodies formation and teratoma assay. hiPSCs were differentiated to cardiac derivatives such as CMs, ECs and CFs, followed by cell markers characterizations (IF, FACS, qRT-PCR) and functional assessments. 3D cMTs were generated by aggregation of 70% CMs, 15% ECs and 15% CFs. After 21 days in culture, structural and metabolic properties of 3D cMTs were examined by IF, qRT-PCR and Seahorse bioanalyzer. hiPSCs demonstrated typical colony-like morphology, normal karyotype, presence of pluripotency markers, and ability to differentiate into cells originating from all three germ layers. hiPSC-CMs showed spontaneous beating and expression of cardiac markers (cTnT, MYL7, NKX2.5, MYH7). hiPSC-ECs formed sprouting spheres and tubes and expressed CD31 and CD144. hiPSC-CFs presented spindle-shaped morphology and expression of vimentin, collagen 1 and DDR2. Self-aggregation of CMs/ECs/CFs allowed development of contracting 3D cMTs, demonstrating spherical organization of the cells, which partially resembled the cardiac muscle, both in structure and function. IF analysis confirmed the expression of cTnT, CD31, CD144 and DDR2 in generated 3D cMTs. RA cMTs exhibited significantly greater formation of capillary-like structures, mimicking enhanced vascularization—key RA feature—compared to control cMTs. Seahorse examination of cMTs revealed changes in mitochondrial and glycolytic rates in the presence of metabolic substrates and inhibitors. The cMTs model may represent an advanced human stem cell-based platform for modeling CV complications in RA. The highly developed capillary-like structures observed within RA cMTs highlight a critical feature of inflammation-induced CV dysfunction in chronic inflammatory diseases.


  • Enriching Cardiomyocytes Derived from hiPSCs by Magnetic-Activated Cell Sorting (MACS)

    by Jan Wolnik, Patrycja Adamska, Aleksandra Oleksy, Józef Dulak, Monika Biniecka

    Cardiomyocytes (CMs) derived from human-induced pluripotent stem cells (hiPSCs) are considered a promising platform for multiple applications, including disease modeling, regenerative medicine, screening of drug toxicity and investigation of cardiomyogenesis. Despite remarkable improvement in methodology enabling differentiation of hiPSCs into CMs, applied protocols generate heterogeneous cell populations composed of CMs along with differentiated non-cardiac cell-types and undifferentiated hiPSCs. Here we describea procedure of automated Magnetic-Activated Cell Sorting (autoMACS) for the purification of hiPSCs-derived CMs under sterile culture conditions. We illustrate that this approach led to a robust depletion of non-cardiac cells and enrichment of CMs, a result particularly crucial for hiPSC lines with poor cardiac differentiation efficiencies.


  • Open Access

    Generation of two induced pluripotent stem cell lines from psoriatic patient with cardiovascular comorbidity

    by Eda Dev, Patrycja Adamska, Jan Wolnik, Aleksandra Oleksy, Zuzanna Piętowska, Adam Zalewski, Joanna Maj, Józef Dulak, Monika Biniecka


  • Open Access

    Generation of two hiPSC lines, (DMBi003-A and DMBi004-A), by reprogramming peripheral blood mononuclear cells and fibroblast-like synoviocytes from rheumatoid arthritis patients

    by Jan Wolnik, Grzegorz Kubiak, Marta Skoczyńska, Piotr Wiland, Ursula Fearon, Douglas Veale, Józef Dulak, Monika Biniecka


  • Insulin‐Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach

    by Lorna Gallagher, Sian Cregan, Monika Biniecka, Clare Cunningham, Douglas J. Veale, David J. Kane, Ursula Fearon, Ronan H. Mullan

    Objective: To investigate a role for insulin‐resistant pathways in inflammation and therapeutic targeting for disease modification in rheumatoid arthritis (RA).Methods: RA disease activity and cardiovascular risk factors, including insulin resistance and body mass index (BMI), were assessed in an Irish RA cohort. Glucose transporter 1 (GLUT‐1) and GLUT‐4 activity in RA and osteoarthritis (OA) synovial tissue was examined using immunohistochemistry. Spontaneous release of proinflammatory mediators from ex vivo RA synovial explants and primary synovial fibroblast (SF) cell culture supernatants was quantified by enzyme‐linked immunosorbent assay. Phosphorylated AMP‐activated protein kinase (p‐AMPK) and GLUT‐1 protein expression was analyzed by Western blotting. Cellular glycolytic and oxidative phosphorylation was assessed using extracellular flux analysis.Results: Insulin resistance was independently associated with both BMI (unstandardized coefficient B 0.113 [95% confidence interval (95% CI) 0.059–0.167]; P < 0.001) (n = 61) and swollen joint count in 28 joints (SJC28) (B 0.114 [95% CI 0.032–0.197]; P = 0.008) (n = 61). Increased GLUT‐1 expression in RA synovium (n = 26) versus OA synovium (n = 16) was demonstrated (P = 0.0003), with increased expression in the lining, sublining, and vascular regions. In contrast, decreased GLUT‐4 expression in the RA lining layer (n = 21) versus the OA lining layer (n = 8) was observed (P = 0.0358). Decreased GLUT‐1 protein expression was observed in parallel with increased p‐AMPK protein expression in SFs in the presence of metformin (n = 4). Metformin increased glycolytic activity and decreased oxidative phosphorylation in RASFs (n = 7) (P < 0.05 for both). Metformin or aminoimidazole carboxamide ribonucleotide presence decreased spontaneous production of interleukin‐6 (IL‐6), IL‐8, and monocyte chemotactic protein 1 in RA synovial explants and SFs (n = 5–7).Conclusion: Insulin resistance is significantly associated with BMI and synovitis in RA, suggesting distinct interplay between glucose availability and inflammation in RA. Furthermore, the effect of metformin on proinflammatory mechanisms suggests a role for AMPK‐modifying compounds in the treatment of RA.


  • Increased T Cell Plasticity With Dysregulation of Follicular Helper T, Peripheral Helper T, and Treg Cell Responses in Children With Juvenile Idiopathic Arthritis and Down Syndrome–Associated Arthritis

    by C. Foley, A. Floudas, M. Canavan, M. Biniecka, E. J. MacDermott, D. J. Veale, R. H. Mullan, O. G. Killeen, U. Fearon

    Objective: Juvenile idiopathic arthritis (JIA) is the most common inflammatory arthritis in children; however, an aggressive, erosive arthritis of little‐known immunologic mechanism occurs 20 times more frequently in children with Down syndrome. This study was undertaken to characterize T cell and B cell polyreactivity, follicular helper T (Tfh) cell, peripheral helper T (Tph) cell, and Treg cell responses, and synovial inflammation in Down syndrome–associated arthritis (DA).Methods: Multiparametric flow cytometric analysis and Simplified Presentation of Incredibly Complex Evaluations (SPICE) software were used to examine peripheral blood B cell populations and T cell cytokine responses in patients with DA, JIA, Down syndrome (trisomy 21 [T21]), and in healthy controls. Tfh and Tph cell frequency and origin, in addition to Treg cell frequency, were also evaluated. Synovial inflammation was assessed by immunohistology.Results: Expansion of IgM‐only memory B cells was demonstrated in DA compared to JIA (mean ± SEM 22.48 ± 3.278 versus 9.011 ± 1.317; P = 0.005), paralleled by decreased frequency of transitional B cells. T cell responses in DA were characterized by marked functional plasticity, as was evident from the increased frequency of polyfunctional CD8+ Th cells (P < 0.05), CD161+ Th cells (P < 0.05), and CD8− Th cells (P < 0.001), and positivity for tumor necrosis factor, interferon‐γ, interleukin‐17A, or granulocyte–macrophage colony‐stimulating factor, compared to all other groups. Significant expansion of CXCR3+CCR6+ (Th1/Th17) Tfh cells (P = 0.003) and CXCR3+CCR6+ Tph cells (P = 0.01), paralleled by a decrease in CXCR3−CCR6− (Th2) Tfh cells was observed in DA compared to T21. Treg cells were significantly reduced in DA compared to T21 (mean ± SEM 7.111 ± 0.9518 versus 11.96 ± 1.055 versus; P = 0.0028), with a specific reduction in the naive:memory Treg cell ratio. Marked synovial tissue inflammation and increased T cell and B cell infiltrations were demonstrated in DA compared to JIA.Conclusion: DA is more common and more aggressive than JIA. It is characterized by increased polyreactive Th, Tfh, and Tph cell responses, reduced Treg cell frequency, and evidence of increased synovial inflammation, all of which are potentially distinct from JIA and T21.


  • Open Access

    Dysregulated miR-125a promotes angiogenesis through enhanced glycolysis

    by Sarah M. Wade, Nils Ohnesorge, Hayley McLoughlin, Monika Biniecka, Steven P. Carter, Michelle Trenkman, Clare C. Cunningham, Trudy McGarry, Mary Canavan, Breandán N. Kennedy, et al.


  • Open Access

    Right Heart Catheterization—Background, Physiological Basics, and Clinical Implications

    by Grzegorz M. Kubiak, Agnieszka Ciarka, Monika Biniecka, Piotr Ceranowicz

    The idea of right heart catheterization (RHC) grew in the milieu of modern thinking about the cardiovascular system, influenced by the experiments of William Harvey, which were inspired by the treatises of Greek philosophers like Aristotle and Gallen, who made significant contributions to the subject. RHC was first discovered in the eighteenth century by William Hale and was subsequently systematically improved by outstanding experiments in the field of physiology, led by Cournand and Dickinson Richards, which finally resulted in the implementation of pulmonary artery catheters (PAC) into clinical practice by Jeremy Swan and William Ganz in the early 1970s. Despite its premature euphoric reception, some further analysis seemed not to share the early enthusiasm as far as the safety and effectiveness issues were concerned. Nonetheless, RHC kept its significant role in the diagnosis, prognostic evaluation, and decision-making of pulmonary hypertension and heart failure patients. Its role in the treatment of end-stage heart failure seems not to be fully understood, although it is promising. PAC-guided optimization of the treatment of patients with ventricular assist devices and its beneficial introduction into clinical practice remains a challenge for the near future.